On May 11, 2026 Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, reported the identification of CDH1 (E-cadherin) as a novel immune-activating target for antibody-drug conjugates (ADCs), and the first presentation of preclinical data on PHST677, the company’s CDH1-targeting bispecific ADC, at the PEGS Boston Summit 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s presentation marks an important milestone for Pheast, representing the first public disclosure of CDH1 as a novel immune-regulatory ADC target," said Roy Maute, Ph.D., Co-founder and Chief Executive Officer of Pheast Therapeutics. "PHST677, designed to combine immune activation with targeted cytotoxicity, demonstrates how our discovery platform and deep engineering capabilities can unlock targets previously inaccessible to traditional ADC approaches. The data presented also reflects our continued expansion into ADCs and the broadening of our pipeline beyond monoclonal antibodies, highlighting the versality of our platform to generate differentiated therapies across multiple modalities."

CDH1, a cell surface protein previously known for its role in cell-cell adhesion was identified by Pheast’s proprietary functional genomic screening platform as a negative regulator of macrophage phagocytosis. This newly defined role positions CDH1 as a novel immuno-oncology target and reveals significant upregulation across multiple solid tumor types.

An anti-CDH1 monoclonal antibody demonstrated robust single-agent efficacy in preclinical tumor models, providing initial validation of CDH1 as a therapeutic target. Pheast developed PHST677, a bispecific ADC designed to combine CDH1-mediated macrophage-driven tumor clearance with tumor-selective targeting via Nectin-4. Importantly, the cytotoxic payload enables direct killing of tumor cells, complementing immune-mediated clearance.

"What differentiates PHST677 is that the CDH1 arm actively engages the immune system at the tumor site, rather than acting solely as a targeting mechanism," said John S. Burg, Ph.D., Senior Director of Protein Sciences at Pheast Therapeutics. "By combining the CDH1 blockade with Nectin-4-directed payload delivery, we’re pairing direct tumor-killing activity with macrophage activation. Together, these orthogonal mechanisms represent a truly differentiated approach to ADC design."

CDH1 and Nectin-4 are co-expressed across multiple solid tumors, including breast, bladder, colorectal, lung, and gastric cancers. The bispecific design restricts payload delivery to cells expressing both targets, improving selectivity and reducing on-target, off-tumor toxicity. Preclinical studies demonstrated selective internalization and efficacy in breast and bladder cancer xenograft models, supporting the therapeutic potential of PHST677.

Pheast’s pipeline now spans two distinct macrophage checkpoint targets across two modalities. The company’s lead program, PHST001, an anti-CD24 monoclonal antibody, is currently in Phase 1 clinical trials for advanced solid tumors and has received FDA Fast Track Designation for ovarian cancer. The advancement of PHST677 expands Pheast’s footprint into ADCs and reinforces the continued productivity of its discovery platform.

PEGS Boston Summit Presentation Details:

Presentation Title: "Coupling Tumor-Specific Payload Delivery with a Novel Target for Immune Engagement"

Presenter: John Burg, Ph.D., Senior Director of Protein Sciences, Pheast Therapeutics

Session Date & Time: Monday, May 11, 2026 at 11:30 AM ET

About CDH1

CDH1 (E-cadherin) is a cell surface protein that mediates cell-cell adhesion in epithelial tissues and is significantly upregulated in multiple human cancers. Through functional genomic screening, Pheast identified CDH1 as a novel negative regulator of macrophage phagocytosis. CDH1 acts as a "don’t eat me" signal that enables tumor cells to evade innate immune clearance. With no previously published role in immune regulation, CDH1 offers a potentially first-in-class macrophage checkpoint mechanism distinct from known macrophage checkpoints such as the CD47–SIRPα and CD24–Siglec-10 axes. Blocking CDH1 increases tumor cell susceptibility to macrophage-mediated phagocytosis and weakens the cell-cell interactions that would otherwise limit access by immune cells and therapeutic agents. CDH1 is co-expressed with Nectin-4 across multiple solid tumor types, making it a compelling target for combination therapeutic strategies.

(Press release, Pheast Therapeutics, MAY 11, 2026, View Source [SID1234665473])

On May 11, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported first quarter 2026 financial results and provided updates on its lead clinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We made meaningful progress in the first quarter advancing our oncology programs and expanding the clinical evidence supporting their potential," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics. "We are particularly encouraged by the breadth of data emerging across our pipeline, which will be featured at the ASCO (Free ASCO Whitepaper) annual meeting, and we believe these programs are well positioned to address important unmet needs in oncology. With a strong balance sheet, we remain focused on disciplined execution as we advance toward additional clinical milestones this year."

Clinical Updates
Eikon continues to advance its lead programs and reports the following updates through the end of the first quarter of 2026:

EIK1001 is a systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. Phase 1 studies have previously shown that EIK1001 exhibits single-agent activity in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. The program continues to advance across multiple clinical trials in melanoma and non-small cell lung cancer ("NSCLC"). Three abstracts have been accepted for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") annual meeting, including an updated data set from a now fully enrolled Phase 2 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for NSCLC. The updated data set includes a full interim data readout of the non-squamous cohort and a partial interim data readout of the squamous cohort. In addition, we expect to make a Trial-in-Progress presentation to highlight an ongoing Phase 2/3 trial of EIK1001 in combination with pembrolizumab for advanced melanoma, as well as the initiation of a Phase 2/3 trial in combination with pembrolizumab and chemotherapy for stage 4 NSCLC.

EIK1003 is a next-generation, highly selective PARP1 inhibitor that has been observed to leave PARP2 signaling intact. PARP2 inhibition may be a key driver of the hematological toxicity associated with first generation, non-selective PARP inhibitors. The program is advancing through an ongoing Phase 1/2 trial in patients with breast, ovarian, prostate, or pancreatic cancer. An abstract has been accepted for presentation at the ASCO (Free ASCO Whitepaper) annual meeting, including updated data from Cohort 1A evaluating EIK1003 as a monotherapy and Cohort 1C evaluating EIK1003 in combination with paclitaxel in patients with platinum-resistant ovarian cancer, or breast cancer patients who are either Her-2 negative, ER+, and hormonal therapy-experienced, or ER- and chemotherapy-experienced. The dose escalation portion of the trial has been completed for Cohorts 1A, 1B (in prostate cancer patients in combination with the novel hormonal agent, abiraterone, and prednisone), and 1C, with backfill nearing completion. Separately, the first patient has been dosed in a Phase 2 dose optimization trial. In addition, global site selection has been initiated for Cohort 1D, which will evaluate EIK1003 in combination with paclitaxel and platinum-based chemotherapeutic agents in patients with breast or ovarian cancer.

EIK1005 is a WRN helicase inhibitor with demonstrated in vitro activity in MSI-high cancer cells. EIK1005 was optimized using Eikon’s technology platform, which includes its imaging instruments that permit single molecule tracking in living cells. The program has advanced into clinical development, with a Phase 1/2 trial underway in patients with advanced solid tumors, which began dosing in February 2026. Two abstracts have been accepted for presentation or publication at the ASCO (Free ASCO Whitepaper) annual meeting, including data on pharmacokinetics and pharmacodynamics in healthy volunteers and resulting dose modeling, as well as a Trial-in-Progress presentation for the ongoing Phase 1/2 trial.

First Quarter 2026 Financial Results

Cash Position: As of March 31, 2026, Eikon had cash, cash equivalents, and marketable securities of $596.0 million. Eikon expects its current cash, cash equivalents, and marketable securities, to fund operations into the second half of 2027.

Research and Development ("R&D") expenses: R&D expenses were $70.0 million for the first quarter of 2026 compared to $56.6 million for the first quarter of 2025, an increase of $13.5 million, or 24%. The increase was primarily due to accelerating clinical trial activity and a $5.0 million milestone payment to Impact Therapeutics (Shanghai) Inc. in the first quarter of 2026 for advancement of EIK1003 into Phase 2 development.

General and Administrative ("G&A") expenses: G&A expenses were $17.3 million for the first quarter of 2026 compared to $14.8 million for the first quarter of 2025, an increase of $2.5 million, or 17%. The increase was primarily due to higher depreciation expense following the occupation of Eikon’s Millbrae headquarters in April 2025 and higher professional fees, insurance expenses, and recruitment fees.

Net Loss: Net loss attributable to common stockholders was $83.0 million for the first quarter of 2026, as compared to $74.5 million for the prior-year period.

(Press release, Eikon Therapeutics, MAY 11, 2026, View Source [SID1234665472])

On May 11, 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, reported financial results for the quarter ended March 31, 2026, and provided recent corporate and clinical updates. "We remain focused on advancing the Phase 2 AMPLIFY-7P trial and anticipate reaching the event-driven primary DFS analysis of ELI-002 7P in post-resection KRAS-driven PDAC mid-year 2026," said Robert Connelly, Chief Executive Officer of Elicio. "We are encouraged by the durability of T-cell responses and clinical observations to date, supporting the potential of ELI-002 7P to favorably impact outcomes as monotherapy in the adjuvant PDAC setting. With our cash runway now expected to extend into Q4 2026, beyond the anticipated DFS readout, we believe we are well positioned to execute on this key milestone and further advance our amphiphile ("AMP") platform in KRAS-mutant pancreatic cancer and other indications, with the goal of delivering meaningful long-term value for patients and shareholders."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Updates on the AMPLIFY-7P Phase 2 Trial

The event-driven primary DFS endpoint analysis for Elicio’s randomized Phase 2 AMPLIFY-7P trial in post-resection mKRAS PDAC is anticipated mid-year 2026
Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial
The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes
Following completion of the primary DFS endpoint analysis, the Company plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") to align on the Phase 3 trial design for ELI-002 7P in resected mKRAS PDAC and to advance ELI-002 7P toward initiation of a registrational study
First Quarter 2026 Financial Results

R&D expenses were $6.8 million for the three months ended March 31, 2026, compared to $7.8 million for the three months ended March 31, 2025. The decrease in R&D expenses was primarily due to lower clinical trial costs as the Phase 2 study of ELI-002 7P continues and the patients moved out of the active dosing phase and into the follow up phase of the trial.

G&A expenses were $3.8 million for the three months ended March 31, 2026, compared to $3.0 million for the three months ended March 31, 2025. The increase in G&A expenses was primarily due to increased Company headcount resulting in increased personnel costs and a slight increase in professional fees.

Net loss was $11.8 million for the three months ended March 31, 2026, compared to $11.2 million for the three months ended March 31, 2025. Net loss for the three months ended March 31, 2026 includes $1.0 million of non-cash other expense primarily resulting from the change in fair value of the warrant liability. Net loss per share for the three months ended March 31, 2026 was $0.65, compared to $0.87 for the three months ended March 31, 2025.

Cash and cash equivalents were $14.9 million as of March 31, 2026, compared to $18.6 million as of December 31, 2025.

The Company raised net proceeds of $8.0 million in Q1 2026 and an additional $5.0 million in Q2 2026 to date, for aggregate net proceeds of approximately $13.0 million, through its established at-the-market program.

The Company expects its current cash and cash equivalents to support planned operations into Q4 2026, beyond the anticipated AMPLIFY-7P Phase 2 event-driven DFS analysis expected mid-year 2026.

ELICIO THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)

Three Months Ended March 31
2026 2025
Operating expenses:
Research and development $ 6,757 $ 7,778
General and administrative 3,845 2,958
Total operating expenses 10,602 10,736
Loss from operations (10,602 ) (10,736 )
Total other expense, net (1,221 ) (473 )
Net loss (11,823 ) (11,209 )
Other comprehensive gain:
Foreign currency translation adjustment 5 31
Comprehensive loss $ (11,818 ) $ (11,178 )
Net loss per common share, basic and diluted $ (0.65 ) $ (0.87 )
Weighted average common shares and pre-funded warrants outstanding, basic and diluted 18,211,745 12,950,574

ELICIO THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

March 31, 2026 December 31, 2025
Assets
Cash and cash equivalents $ 14,948 $ 18,563
Other current assets 1,252 748
Total current assets 16,200 19,311
Other assets 6,489 6,551
Total assets $ 22,689 $ 25,862

Liabilities and stockholders’ equity (deficit)
Current liabilities $ 7,229 $ 8,110
Long-term liabilities 16,897 16,116
Total liabilities 24,126 24,226

Total stockholders’ equity (deficit) (1,437 ) 1,636

Total liabilities and stockholders’ equity (deficit) $ 22,689 $ 25,862

(Press release, Elicio Therapeutics, MAY 11, 2026, View Source [SID1234665471])

On May 11, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported a business update and announced results for the quarter ended March 31, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position," said Thijs Spoor, Perspective’s CEO. "Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain – from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing – differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026."

Clinical Highlights

VMT-α-NET

We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).

Updated interim data from the study, as of a data cut-off (DCO) date of March 4, 2026, were presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in April 2026.

As of April 30, 2026, the first 23 patients in Cohort 2 have had the opportunity for at least 60 weeks of follow-up since beginning treatment. By late 2026, all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment.

We believe our clinical data package positions us for meaningful regulatory engagement in 2026 to align on the path forward.

As of April 30, 2026, a total of 20 patients have been treated in Cohort 3. This cohort is now closed to enrollment. By late 2026, the eight patients initially enrolled for dose-limiting toxicity (DLT) assessment will have had the opportunity for at least 48 weeks of follow-up since beginning treatment.

Cohort 4 is now open for recruitment.

During the dose-finding phase of the study, we enrolled primarily NET patients whose disease originated in the pancreas or the digestive tract. We have an allowance for enrollment of NET patients whose disease originated in the lung (of which small cell lung cancer is a subset), pheochromocytoma/paraganglioma NETs, and SSTR2+ meningioma.

We opened a proof-of-concept cohort of meningioma patients. To date, there is no approved systematic therapy for this disease. The unmet medical need may support an expedited development path.

VMT01

VMT01 is an MC1R-targeted RPT that can be radiolabeled with either 203Pb for patient selection and dosimetry assessment or 212Pb for alpha-particle therapy. We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05655312) in heavily pre-treated patients with histologically confirmed melanoma and MC1R-positive imaging scans.

Since dosing re-opened for 3.0 mCi of VMT01 as monotherapy, and was initiated for 3.0 mCi of VMT01 in combination with nivolumab in September 2025, 10 patients had received VMT01 3.0 mCi treatment as of February 28, 2026; six patients had received VMT01 at 3.0 mCi in combination with nivolumab, and four patients had received 3.0 mCi of VMT01 as monotherapy, in addition to the three patients who received this monotherapy dose in late 2023. Both cohorts are now closed for enrollment.

By late 2026, the 10 patients who had received VMT01 3.0 mCi treatment since the initiation or re-opening of these cohorts in September 2025 will have had the opportunity for at least 24 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to three doses every eight weeks).

PSV359

We designed PSV359 to target and deliver 212Pb to tumor sites expressing fibroblast activation protein-α (FAP-α), which is associated with multiple highly prevalent solid tumors, in patients in need of additional treatment options.

As of April 30, 2026, two patients in Cohort 1 had been treated with [212Pb]PSV359 at 2.5 mCi, and seven patients in Cohort 2 had been treated at 5.0 mCi, for a total of nine patients. By late 2026, these patients will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to four doses every eight weeks).

Cohort 3 is now open for recruitment.

Updates to the preclinical pipeline

Our discovery team is preparing additional novel constructs for potential first-in-human (FIH) imaging.

In May 2026, we presented an FIH image for PSV594, designed to target and deliver 212Pb to tumor sites expressing the Cholecystokinin 2 Receptor (CCK2R), which is expressed across a range of hard-to-treat cancers. The targeting moiety may also be radiolabeled with 203Pb or 68Ga to detect CCK2R expression in-vivo. Preclinical and FIH images suggest the targeting moiety has clean, precise tumor uptake with limited kidney retention, which may result in a desirable therapeutic index.

Updates on manufacturing infrastructure

We continue to make progress on expanding our manufacturing capabilities by increasing and enhancing capacity at existing facilities and building out recently acquired sites.

Our flagship site in the Chicago area is on track to complete construction this year. We are building a complementary site in the Los Angeles area and have plans beyond our current footprint.

First Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of March 31, 2026, were approximately $271 million as compared to $145 million as of December 31, 2025. In February 2026, we announced the closing of an underwritten offering of securities with net proceeds of approximately $164 million after deducting underwriting discounts and commissions and other offering-related expenses. We believe our cash, cash equivalents, and short-term investments as of March 31, 2026, will be sufficient to fund our current clinical milestones and operational investments into late 2027.

As of March 31, 2026, we had approximately 114.0 million shares of common stock and approximately 20.5 million warrants and options to purchase shares of common stock outstanding. In connection with the February 2026 underwritten offering of securities noted above, we issued 39.6 million shares of common stock along with pre-funded warrants to purchase 6.6 million shares of common stock.

Research and development expenses were $21.4 million for the three months ended March 31, 2026, compared to $14.3 million for the three months ended March 31, 2025, an increase of approximately 50%. The increase in research and development expenses was primarily related to higher personnel costs, including share-based compensation, due to additional headcount to support our ongoing clinical trials, as well as increased spending on contract development and manufacturing organizations, clinical site activities, drug programs and delivery, pipeline studies and consulting.

General and administrative expenses were $7.0 million for the three months ended March 31, 2026, compared to $7.8 million for the three months ended March 31, 2025, a decrease of approximately 10%. The decrease in general and administrative expenses was primarily due to decreased fees for professional and consulting services and fees related to operating as a public company, partially offset by increased personnel costs.

Net loss for the three months ended March 31, 2026, was $26.2 million, or $0.25 per basic and diluted share, compared to a net loss of $18.2 million, or $0.25 per basic and diluted share, for the same period in 2025. During the three months ended March 31, 2026 and 2025, there was a net benefit of $2.1 million and $2.3 million, respectively, in net interest income and other expenses. In addition, during the three months ended March 31, 2025 we recognized $1.4 million of Deferred Income, which was received in 2024.

(Press release, Perspective Therapeutics, MAY 11, 2026, View Source [SID1234665470])

On May 11, 2026 CG Oncology, Inc. (NASDAQ: CGON) reported its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gathering of urologists and urologic professionals, showcasing the latest advances in urologic medicine, clinical research and patient care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Results from CORE-008 Cohort CX
Title: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Poster Presentation May 15, 2026, 3:30 – 5:30 PM ET
Podium Presentation at the SUO 2026 Annual Meeting at the AUA May 16, 2026, 4:25–4:30 PM ET
Additionally, the grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA. This Fellowship is designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). Details of the presentations are below:

Grant Recipient Taylor A. Goodstein, MD Presents: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies
May 16, 4:45 PM-4:50 PM ET
Grant Recipient Saum B. Ghodoussipour, MD Presents : Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer
May 16, 4:50 PM-4:55 PM ET
Attendees of AUA 2026 are encouraged to visit CG Oncology at booth #3051 to learn more about the company’s clinical development program and its commitment to advancing innovative therapies for patients with bladder cancer.

(Press release, CG Oncology, MAY 11, 2026, View Source [SID1234665469])